Omada Health
HealthcareNASDAQ:OMDA · NASDAQ Global Market
-$0.59 today
Vol 0.67M · Avg 1.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-5.6%
avg -48.3%
ROIC
-5.2%
avg -34.6%
ROA
-4.2%
avg -26.7%
Analysis
ROA is currently the strongest return metric at -4.2% versus its period average of -26.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sean Duffy | Co-Founder, Chief Executive Officer & Director | $1.97M | — | 42 | $436,271.00 | 0.73% |
Wei-Li Shao | President | $1.66M | — | 55 | $320,827.00 | 0.54% |
Steven L. Cook | Chief Financial Officer | $887,672.00 | — | 40 | $194,009.00 | 0.33% |
Tom Scales | Senior Vice President of Sales & Payer Access | — | — | — | — | — |
William Dougherty | Chief Information Security Officer | — | — | — | — | — |
Danika R. Harrison | Chief Product & Growth Officer | — | — | 50 | — | — |
Allan Kells | Vice President of Investor Relations | — | — | — | — | — |
Sunil Kayiti | Chief Technology Officer | — | — | — | — | — |
Nancy Vitale | Chief People Officer | — | — | 55 | — | — |
Craig Gracey | Chief Accounting Officer | — | — | 35 | $16,470.00 | 0.03% |
Thomas Tatwah Tsang FACP | Chief Medical Officer | — | — | — | — | — |
Jennifer Becker | Chief Care Delivery Operating Officer | — | — | — | — | — |
Lauren Fix | Senior Vice President of Corporate Strategy & Operations | — | — | — | — | — |
Nathan Salha | General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$4.66M
Net Sentiment
$4.66M
Net selling
Most Active
Duffy Sean P.
6 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $4.66M over the last 12 months. That adds up to net selling of $4.66M. Duffy Sean P. was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +42.9% | +17.3% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +42.9% over three years. Forward estimates point to Revenue at +17.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
10x Genomics, Inc.
NASDAQ:TXG
$3.66B
Progyny, Inc.
NASDAQ:PGNY
$2.09B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.83B
UFP Technologies, Inc.
NASDAQ:UFPT
$1.82B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$1.17B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Phreesia, Inc.
NYSE:PHR
$560.02M
Who manages OMDA?
Omada Health (OMDA) lists 14 active executives. The top listed executive is Tom Scales, Senior Vice President of Sales & Payer Access.
Are OMDA insiders buying or selling?
Recent insider activity shows net selling of $5.08M.
Explore More
Continue the stock analysis
Jump to another research area for this company.